Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger
Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger
Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger
Submitted by
admin
on October 9, 2015 - 11:04am
Source:
BioPharma Dive
News Tags:
Allergan
Valeant Pharmaceuticals
drug pricing
Martin Shkreli
Headline:
Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger
Do Not Allow Advertisers to Use My Personal information
